Mode
Text Size
Log in / Sign up
Phase 1 Completed N=57 Randomized Quadruple-blind Treatment

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Pediculosis
Source: ClinicalTrials.gov NCT01518699 ↗
Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcomePrimary: Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF — -9.7; -9.2; 6.1 milliseconds

Summary

The purpose of this study is to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers.

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF
-9.7; -9.2; 6.1

Eligibility Criteria

Inclusion Criteria

  • healthy male or female subject, 18 to 50 years of age, inclusive, at least 45 kg and has a body mass index (BMI) of 18 to 33 kg/m2,
  • Female subjects of childbearing potential must not be pregnant and not lactating or prepared to practice highly effective birth control methods
  • The subject has normal 12-lead ECG results or, if abnormal, the abnormality is not clinically significant (as determined by the investigator).

Exclusion Criteria

  • has evidence of cardiac conduction abnormalities
  • history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative due to cardiac causes at a young age
  • potassium, calcium, or magnesium levels that are below the clinical laboratory's lower limit of normal
  • laboratory test results at Screening are >2 x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), >1.5 x ULN for bilirubin, or >1.5 x ULN for creatinine
  • history or evidence of any clinically significant (as determined by the investigator) cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy (excluding non-melanoma skin cancer)
  • febrile illness or symptomatic viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week before clinic admission
  • supine mean systolic blood pressure 140 mmHg and a mean diastolic blood pressure 90 mmHg
  • positive for HIV or hepatitis C antibody or hepatitis B antigen (HBsAg)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01518699). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search